NCT02919176View on ClinicalTrials.gov

Brown Fat Activation Study

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

September 1, 2016

Primary Completion Date

February 4, 2019

Study Completion Date

February 4, 2019

Conditions
ObeseMetabolic Syndrome
Interventions
DRUG

Mirabegron

Mirabegron 50 mg/day

DRUG

Pioglitazone

Pioglitazone 30 mg/day

DRUG

Mirabegron and Pioglitazone

Mirabegron 50 mg/day and Pioglitazone 30 mg/day

Trial Locations (1)

40536

Center for Clinical and Translational Science, Lexington

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Philip Kern

OTHER

NCT02919176 - Brown Fat Activation Study | Biotech Hunter | Biotech Hunter